Add to ORKGTo assess the impact of the immunization program with 13-valent Pneumococcal Conjugate Vaccine (PCV13) in adults, from October 2013 in Liguria, Italy, both in terms of effectiveness, and tolerability and safety
Pneumococcal disease epidemiology has changed after introduction of pneumococcal conjugate vaccines....
In Italy, the effectiveness of pneumococcal universal vaccination in preventing vaccine-type invasiv...
In Italy, the effectiveness of pneumococcal universal vaccination in preventing vaccine-type invasiv...
To assess the impact of the immunization program with 13-valent Pneumococcal Conjugate Vaccine (PCV1...
Current strategies to prevent adult pneumococcal disease have been recently reviewed in Italy. We di...
Objectives Current strategies to prevent adult pneumococcal disease have been recently reviewed in I...
Pneumococcal disease epidemiology has changed after introduction of pneumococcal conjugate vaccines....
Pneumococcal disease epidemiology has changed after introduction of pneumococcal conjugate vaccines....
Pneumococcal disease epidemiology has changed after introduction of pneumococcal conjugate vaccines....
Background: In September 2011 the European Medical Agency authorized the use of 13-valent pneumococc...
Streptococcus pneumoniae is currently the leading cause of community-acquired pneumonia (CAP) and lo...
Streptococcus pneumoniae is currently the leading cause of community-acquired pneumonia (CAP) and lo...
Pneumococcal pneumonia has a high clinical burden in terms of morbidity, mortality and hospitalizati...
Current strategies to prevent adult pneumococcal disease have been recently reviewed in Italy. We di...
Objectives Current strategies to prevent adult pneumococcal disease have been recently reviewed in I...
Pneumococcal disease epidemiology has changed after introduction of pneumococcal conjugate vaccines....
In Italy, the effectiveness of pneumococcal universal vaccination in preventing vaccine-type invasiv...
In Italy, the effectiveness of pneumococcal universal vaccination in preventing vaccine-type invasiv...
To assess the impact of the immunization program with 13-valent Pneumococcal Conjugate Vaccine (PCV1...
Current strategies to prevent adult pneumococcal disease have been recently reviewed in Italy. We di...
Objectives Current strategies to prevent adult pneumococcal disease have been recently reviewed in I...
Pneumococcal disease epidemiology has changed after introduction of pneumococcal conjugate vaccines....
Pneumococcal disease epidemiology has changed after introduction of pneumococcal conjugate vaccines....
Pneumococcal disease epidemiology has changed after introduction of pneumococcal conjugate vaccines....
Background: In September 2011 the European Medical Agency authorized the use of 13-valent pneumococc...
Streptococcus pneumoniae is currently the leading cause of community-acquired pneumonia (CAP) and lo...
Streptococcus pneumoniae is currently the leading cause of community-acquired pneumonia (CAP) and lo...
Pneumococcal pneumonia has a high clinical burden in terms of morbidity, mortality and hospitalizati...
Current strategies to prevent adult pneumococcal disease have been recently reviewed in Italy. We di...
Objectives Current strategies to prevent adult pneumococcal disease have been recently reviewed in I...
Pneumococcal disease epidemiology has changed after introduction of pneumococcal conjugate vaccines....
In Italy, the effectiveness of pneumococcal universal vaccination in preventing vaccine-type invasiv...
In Italy, the effectiveness of pneumococcal universal vaccination in preventing vaccine-type invasiv...